logo-loader
viewIntegumen

Integumen unit Labskin unit lands deal with three top-20 cosmetic companies

The new orders will make “full use” of the company’s newly enlarged 3,000-square foot R&D facility in York

Integumen -
The new orders will make “full use” of the company’s newly enlarged 3,000-square foot R&D facility in York

Integumen PLC (LON:SKIN) confirmed it is on track to exceed £1mln in revenues by the year-end as it confirmed its Labskin subsidiary had signed commercial agreements with three companies.

It didn’t reveal the identities of the customers, but said they were top-20 cosmetic firms.

They will be taking microbiome research and development services worth in total a “low six-figure value”. All are expected to ink additional deals after initial trials are completed, Integumen said.

The customers will receive the first commercially available combination of cloned Labskin (a human skin model), microbiome tests and gene sequencing using data analytics on the LabskinAI platform. 

The test are designed to confirm the impact of clients' new products and ingredients on human skin. 

“Each breakthrough and combination of cloned skin, microbiome definition for diseased skin and the data analytic use of AI on the gene sequencing results, without any harm to animals, builds the unique offering of the enlarged group,” said chief executive Gerard Brandon.

“This is why we believe that providing world class services to our prestigious client base in the skin care and cosmetic industries will continue to provide strong growth and new contract revenues into 2020, and ultimately, drive value for our shareholders."

The new orders will make “full use” of the company’s newly enlarged 3,000-square foot R&D facility in York.

Quick facts: Integumen

Price: 1.56 GBX

AIM:SKIN
Market: AIM
Market Cap: £15.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Integumen named herein, including the promotion by the Company of Integumen in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Base Resources assesses mineral sands market conditions and...

Base Resources Limited (ASX:BSE) general manager of marketing Stephen Hay updates Proactive on his recent participation in the annual TZMI mineral sands industry conference in Singapore earlier this month. Mr Hays spoke about how supply constraints were continuing to impact the global market,...

1 week, 4 days ago

2 min read